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ABSTRACT
Keratoconus management has significantly
changed over the last two decades. The advent
of new interventions such as cornea cross-link-
ing, intrastromal corneal ring segments, and
combined treatments provide corneal clinicians
a variety of treatment options for the visual
rehabilitation of keratoconus patients. This
review summarizes current evidence for these
treatments and highlights their place in kera-
toconus management while new promising
emerging therapies are being investigated.
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BACKGROUND
Methods of Literature Research
Medline and PubMed databases were used to
search the keywords keratoconus, contact len-
ses, intrastromal corneal ring segments, cornea
transplantation, and cornea cross-linking from
1990 to 2017. Detailed search was limited to
English-language manuscripts or at least avail-
able abstracts. The authors reviewed a total of
393 abstracts. From these, 126 articles were
considered of clinical relevance to the subject
and were included in the review. This article is
based on previously conducted studies and does
not involve any new studies of human or ani-
mal subjects performed by any of the authors.
Definition
Keratoconus is a progressive, bilateral, asym-
metric, ectatic disease which causes progressive
corneal thinning and protrusion of the cornea
leading to irregular astigmatism and visual
deterioration [1]. The term keratoconus derives
from the Greek words kerato-idis (cornea) and
konos (cone). John Nottingham is considered
the first author to describe keratoconus and its
associations [2]. Interestingly, his proposed
treatment algorithm has many similarities to
the one used today—optical devices being the
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management option of choice in the mild
stages with surgery being a last resort [3].
A recent project using a modified Delphi
method called on experts from around the world
to elucidate the controversies that exist regard-
ing keratoconus and other ectatic disorders [4].
Thirty-six ophthalmologists shared their exper-
tise to come to a consensus regarding definition,
diagnostic methods, and management options
for keratoconus and other ectatic diseases. As a
result, keratoconus was classified under the term
‘‘primary ectatic disease’’ as opposed to other
corneal pathologies which result in cornea thin-
ning without having an ectatic component.
Frequency
Keratoconus typically commences at puberty
and tends to progress until the third or fourth
decade of life [5]. The progression rate of kera-
toconus varies between individuals and is usu-
ally higher in younger patients. The disease
tends to stabilize approximately 20 years fol-
lowing initial presentation [5].
The reported prevalence of keratoconus is
highlyvariable, as it is influencedbymany factors,
such as the selected cohort of patients, the geo-
graphic location, and the criteria used for diag-
nosis. More specifically, prevalence figures vary
worldwide and can range from 0.0003% in Russia
[6] to 2.3% in India [7], while themost frequently
cited prevalence for keratoconus in the literature
is 0.054% in Minnesota in the USA [8]. The
widespread use of corneal topography and com-
mon diagnostic criteria is expected to result in
increased reported prevalence and incidence fig-
ures. In a recent epidemiologic study in the
Netherlands, the annual incidence and preva-
lence of keratoconus were reported to be five- to
tenfold higher than previously estimated [9].
Keratoconus occurs in both genders [8]. No
gender predominance has been reported in several
studies, whereas recent reports have suggested a
higher prevalence among male patients [9, 10].
Risk Factors
The etiology of keratoconus is multifactorial.
Commonly reported risk factors for keratoconus
include family history, ethnicity (Asian and
Arabian), mechanical factors (e.g., eye rubbing,
floppy eyelid), atopy, ocular allergy, Down
syndrome, connective tissue disorders (Marfan
syndrome, Ehlers–Danlos), and Leber’s congen-
ital amaurosis [4, 11].
Morbidity
Visual loss occurs primarily from irregular
astigmatism and myopia due to corneal pro-
trusion, and secondarily from corneal scarring.
Corneal thinning usually occurs in the central
cornea as well as the inferotemporal cornea
[12]. Advanced keratoconus may rarely progress
to corneal hydrops, so-called acute keratoconus,
wherein breaks occur in the Descemet layer, at
times associated with stromal clefts, that cause
aqueous to enter the stroma, leading to stromal
edema and potentially severe corneal scarring.
Patients usually report a sudden loss of vision
and some ocular discomfort in the affected eye
accompanied by limited pain and conjunctival
injection [12].
Keratoconus Diagnosis
Disease detection, especially at early stages, is
essential particularly in preventing iatrogenic
ectasia in patients with subclinical forms of
keratoconus who undergo refractive surgery.
Over the last decade, important improvements
have been reported regarding the diagnosis and
management of keratoconus [13]. Corneal
topography and tomography (Scheimpflug
imaging or anterior segment optical coherence
tomography, OCT) are among the most useful
technologies for the evaluation of the anterior
and posterior corneal surfaces, as they can
generate corneal thickness and elevation maps,
and can provide epithelial imaging and analysis
of the anterior segment [14–16]. Moreover,
instruments evaluating the corneal biome-
chanics provide useful parameters for the diag-
nosis and monitoring of the disease.
Technological advances have increased the
demands for newer classifications systems, as
older ones [e.g. Amsler–Krumeich classification
system (Table 1)], although widely acceptable,
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do not combine topographical and tomo-
graphical indicators or maps and biomechanical
parameters. Valuable information has been
provided for the diagnosis and monitoring of
keratoconus through studies presenting classi-
fication systems based on combined topo-
graphical, tomographical, and biomechanical
parameters [13, 15, 17–20]. Several newly
developed pieces of software such as the
Enhanced Reference Surface and the
Belin–Ambrosio Enhanced Ectasia display can
be employed to detect earlier changes [14].
Keratoconus Progression
According to the Global Consensus on Kerato-
conus and Ectatic Diseases, ‘‘ectasia progres-
sion’’ is defined by a consistent change in at
least two of the following parameters [4]:
1. Steepening of the anterior corneal surface
2. Steepening of the posterior corneal surface
3. Thinning and/or an increase in the rate of
corneal thickness change
However, most clinical trials examining corneal
cross-linking efficacy use the criteria shown in
Table 2 [21].
Progression of keratoconus usually results in
deterioration of best spectacle-corrected visual
acuity (BSCVA). Nevertheless, a decrease in both
uncorrected visual acuity and BSCVA is not
essential to document progression of kerato-
conus. Younger patients should be examined at
shorter time intervals [4].
CURRENT TREATMENT OPTIONS
AND MANAGEMENT
Spectacles and Contact Lenses
in Keratoconus
Spectacles may be used in early keratoconic
cases. It is often difficult to achieve satisfactory
spectacle vision because of various disease fac-
tors, such as high irregular astigmatism and
significant anisometropia. Contact lenses, on
the other hand, can offer satisfactory vision by
addressing refractive errors and anterior cornea
irregularities in keratoconic patients [22].
Table 1 Amsler–Krumeich classiﬁcation system
Stage Findings
1 Eccentric steepening
Myopia, induced astigmatism, or both\5.00 D
Mean central K readings\48 D
2 Myopia, induced astigmatism, or both from 5.00
to 8.00 D
Mean central K readings\53.00 D
Absence of scarring
Corneal thickness[400 lm
3 Myopia, induced astigmatism, or both from 8.00
to 10.00 D
Mean central K readings[53.00 D
Absence of scarring
Corneal thickness 300–400 lm
4 Refraction not measurable
Mean central K readings[55.00 D
Central corneal scarring
Corneal thickness\200 lm
D diopter, K keratometry
Table 2 Criteria used to establish keratoconus progression
in cross-linking clinical trials [21]
Steepest keratometry
(Kmax)
[1 D increase from baseline
Flattest keratometry
(Kmin)
[1 D increase from baseline
Mean keratometry (Kmean) [0.75 D Increase from
baseline
Corneal apex power [1 D increase from baseline
Manifest spherical
equivalent
[0.5 D difference from
baseline
Central corneal thickness [2% decrease from baseline
D diopter
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The type of contact lenses prescribed
depends on the stage of keratoconus [23]. Soft
lenses, soft toric, or custom soft toric contact
lenses may be adequate early in the disease to
correct myopia, regular astigmatism, and mildly
irregular astigmatism. As the disease progresses,
rigid gas-permeable (RGP) lenses or various
specialized lenses, such as hybrid lenses, piggy-
back, or scleral lenses, may be required [23].
Soft corneal contact lenses offer adequate
vision, sufficient tear exchange, corneal oxy-
genation along with ease of handling and low
rates of infection if handled properly. RGPs offer
better vision than soft lenses in more advanced
cases but are often associated with discomfort
and foreign body sensation, difficulty with
centration of the optics in highly decentered
cone apices, and the inability of the lens to be
properly fitted in some advanced cases [24].
Recent developments in lens material and
design, however, have addressed these prob-
lems. In cases of RGP intolerance, both piggy-
back lens combination and hybrid lenses can
improve wearing time [25]. The piggyback
approach incorporates a corneal RGP lens over a
soft silicone hydrogel lens, combining increased
patient comfort with adequate visual perfor-
mance. For example, a soft lens with high pos-
itive power (4D) improves centration of a rigid
lens in case of a sagging cone.
Hybrid lenses consist of a central RGP lens
and a soft peripheral skirt lens [25], thus com-
bining the visual performance of a rigid lens
with the comfort and stability of a soft lens.
Scleral lenses are often reserved for advanced
cases. Current scleral lenses offer good visual
performance and comfort [26].
Advanced high oxygen-permeable lens
materials and unique designs allow higher cor-
neal oxygen supply and tear exchange. Cus-
tomization has been advocated by the use of
anterior segment OCT and various forms of
corneoscleral profile measurement instruments,
greatly improving lens tolerance and visual
outcomes [27].
Intrastromal Corneal Ring Segments
Intrastromal corneal ring segments (ICRS) are
medical devices made of synthetic material
designed to alter the morphology and refractive
power of the cornea. ICRS implantation is a safe
and reversible technique that can achieve cor-
neal flattening and improved visual outcomes.
Several factors such as the type of ICRS, the
insertion technique, and patient selection con-
tribute to the final outcome [28].
Different types of ICRS are currently avail-
able, offering a variety in thickness, diameter,
and ICRS profile (Table 3). Proper selection of
the ICRS depends mainly on the refractive error,
corneal thickness, and keratometry readings of
the keratoconic patient. Smaller ring diameters
offer increased flattening effects and are often
used in patients with higher refractive errors
[29].
Table 3 Characteristics of different types of ICRS
Name Manufacturer Arc
length ()
Thickness
(mm)
Inner diameter
(mm)
Outer
diameter (mm)
Proﬁle
Intacs Addition Technology Inc.
Sunnyvale, CA, USA
150 0.25–0.45 6.8 8.1 Hexagonal
Kerarings Mediphacos Ltd, Belo Horizonte,
Brazil
90–210 0.15–0.35 5.0 6.0 Triangular
Intacs
SK
Addition Technology Inc.
Sunnyvale, CA, USA
150 0.4–0.45 6.0 7.3 Oval
MyoRing Dioptex GmbH, Linz, Austria 360 0.15–0.35 5.0–8.0 5.0–8.0 Triangular
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Proper patient selection is crucial to the final
visual outcome of ICRS implantation. There are
no general guidelines but most authors agree
that patients should meet the following criteria:
• Corrected distance visual acuity below 0.9 in
the decimal score
• Intolerance to contact lens use
• Absence of cornea scarring
The creation of channels deep into the cor-
nea (70–80% of total corneal thickness), where
the segments will be inserted, can be achieved
either by the mechanical technique or the use
of femtosecond laser [30]. Femtosecond laser
tunnel creation has enhanced safety in ICRS
implantation by ensuring an accurate and pre-
cise depth of implantation and reducing the risk
of operative and postoperative complications.
To date, there are no established nomograms
for the procedure and most researchers use
empirical data and subjective analysis. The
number of segments implanted, the location of
insertion, and the use of multiple segments of
different styles vary among studies. Regarding
the number of segments, Alio et al. reported
that the number of implanted segments should
be decided according to the topographic pattern
of the keratoconus: in cases of central cones
implantation of two segments offers optimum
results, while in cases of inferior steepening one
implant should suffice [31]. Siganos et al.
reported satisfactory visual results after
implantation of two segments of 160 arc
length while adjusting the thickness according
to the patient’s refractive error [32].
Likewise, there is no agreement concerning
the location of the implant. Some authors
report better visual outcomes when the corneal
incision is made on the temporal side of the
cornea, whereas others believe that the incision
should be performed in the steepest meridian
[31, 33].
Most authors report satisfactory results after
ICRS implantation in terms of visual acuity and
optical quality. It seems that patients with poor
visual acuity at the time of surgery are more
likely to benefit from the procedure [34, 35].
Furthermore, long-term results seem to depend
on disease progression at the time of surgery,
with stable forms demonstrating favorable out-
comes over a longer period of time [35].
Keratoplasty: Penetrating Keratoplasty
(PK)—Deep Anterior Lamellar
Keratoplasty (DALK)
Until recently, PK has been the treatment of
choice for advanced forms of keratoconus.
However, improvements in operative tech-
niques have increased the popularity of DALK.
The advantages of DALK over classic PK consist
of lower rates of graft rejection, endothelial cell
preservation, avoidance of an open-sky proce-
dure, and shorter period of postoperative
instillation of steroid agents, leading to lower
incidence of postoperative cataract and glau-
coma formation [36]. On the contrary, limita-
tions of the method include the demanding
surgical skills required for the performance of
the DALK technique and the fact that it cannot
be easily applied in corneas with scars, neovas-
cularization, or previous hydrops [37].
Despite the popularity of DALK amongst
corneal surgeons for keratoconus, there is a
paucity of high-quality randomized controlled
trials (RCTs) comparing the two techniques.
The existing evidence confirms reduced rejec-
tion and refractive astigmatism with DALK but
better visual outcomes with PK [38]. However, it
seems that DALK properly performed provides
the same visual outcomes as PK. In studies
where reported DALK visual outcomes were
inferior to PK, this discrepancy has been attrib-
uted to incomplete stromal dissection and
residual stroma over the Descemet membrane
(DM). The poor visual outcomes seem to
depend on the depth of the dissection (not
revealing a bare DM), rather than the regularity
and smoothness of the residual stromal bed [38]
as shown in a recent study which compared
femtosecond laser-assisted descemetic and pre-
descemetic lamellar keratoplasty [39].
Concerning complication rates, reported
incidences of penetrating keratoplasty graft
rejection range from 2.3% to 68% [40–42],
though graft failure rate in these eyes tend to be
less, thanks to immediate application of corti-
costeroid therapy [40]. DALK, on the other
hand, spares transplantation of the endothe-
lium, thus eliminating the possibility of
endothelium rejection. However, epithelial,
stromal, and mixed epithelial and stromal graft
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rejection can occur at a rate of 8–10% [43, 44].
Graft survival is projected to be longer with
DALK [38]. Borderie et al. using a joint regres-
sion model predicted an average life span for PK
grafts of 17.9 years, compared to 49 years with
DALK [45]. The most common complication in
DALK surgery is perforation of the Descemet
membrane during surgery [46]. The risk is less in
elderly patients, who tend to have a thicker
Descemet membrane. Depending on the stage
of the surgery it may be necessary to convert to
PK. Several authors have addressed the problem
and proposed variations in the technique that
reduce the rate of this complication [47, 48].
Recently, the creation of tunnels using fem-
tosecond laser as a pretreatment for the creation
of a big bubble has been proposed by Diakonis
et al. [49], while Siebelmann et al. reported the
increased safety of intraoperative use of OCT in
DALK [50].
Femtosecond laser (FSL) application has
shown promise in improving postoperative
outcomes in both techniques [51, 52]. In PK, the
FSL can achieve a greater precision in cutting
either the donor or the recipient cornea, mini-
mizing misalignments and increasing the sta-
bility of the wound [51]. Furthermore, FSL can
be used to create different wound configura-
tions, not achievable with conventional tre-
phine techniques, such as the top-hat,
mushroom, or zig-zag configurations [52].
Reduced postoperative astigmatism and
increased wound healing may be achieved in
this way. However, reports are conflicting. Farid
et al. [51] compared 49 eyes of 43 patients that
underwent FSL-assisted zig-zag incision pattern
PK vs 17 eyes of 14 patients that underwent
conventional Barron suction trephination PK.
They found that the greatest difference in
astigmatism was observed at month 1, followed
by month 3, when the average astigmatism was
4.5 D in the conventional group vs 3.0 D in the
FSL group. On the other hand, Daniel et al. [53]
found no significant difference in the refractive
and visual outcomes after FSL-assisted PK com-
pared with the guided trephine system kerato-
plasty. Most authors agree that FSL-assisted PK
enables faster and more stable wound healing,
allowing earlier complete suture removal than
conventional PK. Nevertheless, the long-term
refractive outcomes of the two techniques seem
to be the same.
The use of the FSL in DALK allows the cre-
ation of accurate lamellar incisions and side
cuts, facilitating the use of scissors to cut resid-
ual stroma from Descemet membrane and
allowing a more secure wound closure and ear-
lier suture removal [54].
Corneal Cross-Linking
The introduction of cornea cross-linking (CXL)
in the late 1990s has significantly altered the
management of keratoconic patients [55].
Recent studies report a significant reduction in
the annual number of keratoplasties performed
after CXL introduction [56, 57]. Most studies
report a greater than 90% success rate in stabi-
lization of keratoconus progression after CXL
application [55].
In order to achieve a strengthening effect of
corneal tissue and arrest keratoconus progres-
sion, the use of riboflavin (vitamin B2) is com-
bined with ultraviolet A (UV-A) irradiation.
Riboflavin plays the role of a photosensitizer in
the photopolymerization process and when
combined with UV-A irradiation increases the
formation of intrafibrillar and interfibrillar car-
bonyl-based collagen covalent bonds through a
molecular process that has still not been com-
pletely elucidated [58]. The effect of corneal
cross-linking can be identified as a demarcation
line observed during slit lamp examination and
on anterior segment OCT. Many researchers
believe that this demarcation line may act as an
indicator of treatment depth and extent [59].
The standard Dresden protocol includes
removal of the central 8–10 mm of the epithe-
lium and application of a riboflavin solution
(0.1% riboflavin-5-phosphate and 20% dextran
T-500) to the corneal surface 30 min before
irradiation and at 5-min intervals during the
course of a 30-min exposure to 370-nm UV-A
with an irradiance of 3 mW/cm2 [60]. Several
other protocols have been proposed that either
maintain corneal epithelium or reduce exposure
time as described below.
A number of studies have shown the bene-
ficial results of CXL treatment in keratoconus in
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terms of visual acuity and topographic indices
[21, 61–66]. A prospective clinical trial by Hersh
et al. demonstrated improvement in visual
acuity and maximum keratometry in patients
with progressive keratoconus [21]. Vinciguerra
et al. reported improvement in corneal and
total wavefront aberrations as well as in uncor-
rected and corrected visual acuity after a
12-month follow-up following CXL [61]. Wit-
tig-Silva et al. in their prospective, randomized
trial reported statistically significant flattening
of the steepest simulated keratometry value and
improved visual acuity [63]. Interestingly, the
effect of CXL treatment seems to extend beyond
the first months of surgery with long-term fol-
low-ups showing that corneal flattening con-
tinued for up to several years after treatment
[64–66]. Preoperative factors that predict
cross-linking efficacy have not been clearly
established, though it seems that steep corneas
with preoperative keratometry values greater
than 58 D and eccentric cone location have
higher complication rates [67].
In terms of safety, proper application of the
Dresden protocol in patients with corneal
thickness of at least 400 lm is considered a safe
procedure [68]. It should be noted that corneal
thickness measurements should be attained
after epithelial removal and prior to application
of riboflavin and UV-A light exposure in order
to prevent UV toxicity to the endothelium. The
use of hypoosmolar riboflavin is indicated in
patients with borderline corneal thickness to
swell the tissue, though there are some concerns
about increased endothelial toxicity and
reduced treatment efficacy. The majority of
CXL complications arise from epithelial
debridement; these include infection, sterile
infiltrates, delayed re-epithelialization, corneal
edema, and corneal haze [67].
CXL Plus
Corneal cross-linking has proven over the years
to be an effective and safe procedure in arresting
keratoconus progression and increasing corneal
resistance. However, visual rehabilitation for
ectatic corneas also requires improvement in
corneal curvature irregularity and reduction of
the residual refractive error. Several adjuvant
therapies in combination with CXL treatment
have been proposed to not only arrest progres-
sion of keratoconus but also improve functional
vision and delay or even prevent keratoplasty.
The term ‘‘CXL plus,’’ introduced in 2011 by
Kymionis, refers to the several combined
refractive procedures studied to enhance the
CXL result [69].
CXL with topography-guided photorefrac-
tive keratectomy (PRK) was the first combined
CXL treatment performed with the use of the
excimer laser. Several variations of the tech-
nique have been proposed since, related to the
timing of the two procedures (simultaneous or
sequential), maximal recommended ablation
depth, and the use of mitomycin C [70–73].
Regarding the sequence of the procedures,
Kanellopoulos in his comparative study showed
that same-day simultaneous topography-guided
PRK followed by CXL is more effective than
sequential CXL with delayed (6 months or
more) PRK in the visual rehabilitation of ectasia
[70]. The combination of treatments proposed
by his team included sequential excimer laser
epithelial debridement (50 lm), partial topog-
raphy-guided excimer laser stromal ablation,
and high-fluence ultraviolet-A irradiation
(10 mW/cm2), accelerated (10 min) CXL
(Athens protocol) [71]. In a recent attempt to
incorporate cyclorotation compensation in
customized topography-guided treatments the
sequence of procedures has been slightly altered
with partial PRK being performed before the
phototherapeutic keratectomy (PTK) step (en-
hanced Athens protocol) [72].
Regarding mitomycin C use following PRK,
Kanellopoulos used mitomycin C 0.02% for 20 s
[70]. On the other hand, Kymionis et al. avoi-
ded using mitomycin C based on the hypothesis
that cross-linking of the ablated stroma offers
the advantage of depopulating keratocytes in
the anterior stroma, which could reduce the
possibility of haze formation [73].
Anterior cornea remodeling and regression
of anterior cornea irregularities with transep-
ithelial phototherapeutic keratectomy (t-PTK)
prior to CXL application has proven to be a
valuable alternative to mechanical debridement
of cornea epithelium. The Cretan protocol that
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first described the technique and several other
subsequent studies showed improved visual and
refractive outcomes [74, 75]. A potential expla-
nation for the improved results is that per-
forming t-PTK in eyes with keratoconus allows
excimer laser ablation to remove corneal
epithelium along with corneal stromal tissue on
the apex of the cone, thus regularizing the
anterior corneal surface and improving the
efficacy of cross-linking [74].
The combination treatment of corneal
cross-linking and ICRS offers not only stabi-
lization of keratoconus but also improvement
in visual and topographic outcomes in patients
with keratoconus. There are several reports of
promising results [76, 77] with the combined
treatment, although some studies found that
the synergistic effect did not prove superior to
ICRS implantation alone. For example, Cakir
et al. [78] and Ferenczy et al. [79] could not
demonstrate superiority of combined ICRS and
CXL treatment over ICRS treatment alone.
Cornea cross-linking can be performed
before, during, or after ICRS implantation, but
the ideal sequence and timing of this combi-
nation are still uncertain. Liu et al. retrospec-
tively examined 41 eyes that were divided into
three groups. Group 1 underwent sole ICRS
implantation, group 2 underwent ICRS first
followed by CXL immediately after, and group 3
underwent CXL first followed by ICRS long
after. No significant differences were found
among these three groups [80]. On the contrary,
in a prospective randomized study, Coskun-
seven et al. showed that ICRS placement, fol-
lowed by CXL, led to statistically superior
keratometric, refractive, and visual outcomes
than CXL followed by ring implantation [81].
Phakic intraocular lens (PIOL) implantation
in addition to CXL is another alternative com-
bined treatment of keratoconus performed to
optimize the CXL outcome. Three types of PIOL
are currently available for intraocular refractive
correction: angle supported, iris fixated, and
posterior chamber IOL. Although preliminary
results are promising [82–85], long-term ran-
domized comparative prospective studies with
large cohorts are needed to evaluate the stability
and potential complications of the procedure
and to propose alternative treatments in cases
of keratoconus progression and refractive
change.
Treatments that combine cross-linking with
corneal ring segments and PRK have also shown
promising results. Combined treatments have
shown significantly improved uncorrected dis-
tance visual acuity, corrected distance visual
acuity, and central keratometry value, and
consequently visual function, in patients with
moderate keratoconus [86–91]. Long-term fol-
low-up will be important in these patients to
determine the stability of visual outcomes.
Accelerated Cross-Linking
Given the favorable ectasia-stabilizing results
with cornea cross-linking therapy, clinical
efforts are aimed at optimizing the procedure’s
treatment time, intra- and postoperative com-
fort, and efficacy.
For example, accelerated CXL using higher
irradiance UV-A to shorten the amount of time
necessary to deliver the equivalent total energy
dose is a new alternative [92, 93]. This tech-
nique is based on the Bunsen-Roscoe law of
photochemical reciprocity. That is, the same
photochemical effect can be achieved by deliv-
ering a similar total energy over a shorter period
of time.
Several recent in vivo studies using different
protocols showed the procedure to be safe and
effective in stopping ectasia progression
(Table 4). Yıldırım et al. compared 74 eyes trea-
ted with intended UV-A radiance of 5.4 J/cm2
and 72 eyes treated with radiance of 7.2 J/cm2
and found similar refractive and topographic
outcomes in the two groups [94]. Alnawaiseh
et al. used an 18 mW/cm2 for a 5-min protocol
on 28 eyes with mean follow-up time of
21.7 months reporting effective halting of ker-
atoconus progression [95]. Tomita et al. exam-
ined two different riboflavin application times
(15 and 30 min) [96]. In this study, both pro-
tocols had similar outcomes relative to con-
ventional CXL. Regarding the safety and the
recovery time following the procedure, both
Ozgurhan et al. and Hashemian et al. found less
sub-basal nerve disruption using the accelerated
protocols [97, 98].
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Some investigators have observed a shal-
lower postoperative demarcation line, indicat-
ing reduced riboflavin penetration and CXL
treatment depth [106]. However, Kymionis
et al. using modified accelerated protocols
(18 mW/cm2 for 7 min and 9 mW/cm2 for
14 min) found no difference in the depth of the
demarcation line in comparison to standard
CXL [107]. Despite the controversies regarding
the efficacy of accelerated cross-linking, the
technique has been gaining popularity over the
last few years. The protocol which will provide
optimum results is still under investigation.
Table 4 Comparative randomized control trials between accelerated cross-linking protocols vs the Dresden protocol
Author Number of eyes and protocol used Follow-up
(months)
Outcomes
Hashemi
et al. [92]
31 eyes 18 mW/cm2 5 min vs 31 eyes
Dresden protocol
18 Comparable outcomes and safety proﬁle between
methods
Sherif [93] 14 eyes 30 mW/cm2 for 4 min 20 s vs 11
eyes Dresden protocol
12 Both groups had comparable visual acuity
improvement
Ng et al.
[99]
12 eyes 9 mW/cm2 for 10 min vs 14
eyes Dresden protocol
13.9 ± 6.3 Both procedures stopped keratoconus progression.
Conventional group presented greater corneal
ﬂattening, which correlated with a deeper corneal
stromal demarcation line
Razmjoo
et al.
[100]
20 eyes 18 mW/cm2 for 5 min vs 20 eyes
Dresden protocol
6 No signiﬁcant difference in visual acuity, refractive
criteria, and topographic criteria
Cınar et al.
[101]
13 eyes 9 mW/cm2 for 10 min vs 13 eyes
Dresden protocol
6 No statistically signiﬁcant difference in visual and
refractive results between the two groups
Choi et al.
[102]
13 eyes 30 mW/cm2 for 3 min 40 s vs 15
eyes Dresden protocol
6 A-CXL showed a smaller topographic ﬂattening
effect than did the conventional Dresden protocol
Tomita
et al. [96]
30 eyes had 15 min riboﬂavin pre-soak
and 30 mW/cm2 3 min vs 18 eyes
Dresden protocol
12 Both procedures were safe and efﬁcient in halting
keratoconus progression
Shetty et al.
[103]
36 eyes, 3 mW/cm2 for 30 min
36 eyes, 9 mW/cm2 for 10 min
33 eyes, 18 mW/cm2 for 5 min
33 eyes, 30 mW/cm2 for 3 min
12 Conventional CXL and accelerated CXL with
irradiations of 9 and 18 mW/cm2 showed better
visual, refractive, and tomographic results
Sadoughi
et al.
[104]
12 eyes 9 mW/cm2 for 10 min
12 eyes Dresden protocol
12 Similar refractive, visual, keratometric, and
aberrometric results and less adverse effects on the
corneal thickness and endothelial cells on both
groups
Cummings
et al.
[105]
66 eyes, Dresden protocol
36 eyes, 9 mW/cm2 for 10 min
12 Better ﬂattening effect in accelerated group
CXL cornea cross-linking, A-CXL accelerated cornea cross-linking
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Keratoconus Treatment Algorithm
To date, there are no specific guidelines on
keratoconus management. Several treatment
modalities are available and the selection of the
optimum therapy depends on the patient’s
cornea parameters and the rate of keratoconus
progression.
In patients with advanced forms of kerato-
conus (stage IV according to Amsler–Krumeich
classification), the indicated treatment methods
are deep anterior lamellar keratoplasty or pen-
etrating keratoplasty [41, 42]. As previously
mentioned, several parameters such as corneal
thickness, corneal steepness, endothelial cells
dysfunction, crystalline lens opacities, patient’s
age, and corneal scarring need to be considered
before selection of the optimal surgical proce-
dure [42].
In less advanced keratoconic cases (corneal
thickness above 400 lm with transparent cor-
nea) (stage I, II, III), management of the patient
depends on four factors: the age, the stability of
the disease, the spectacles or contact lens tol-
erance, and the degree of corneal irregularity. In
stable cases, if the visual function with specta-
cles or contact lenses is satisfactory, there is no
need for surgical intervention and the patients
should be advised to avoid eye rubbing and
topical antihistaminic agents could be pre-
scribed (Fig. 1). Patients should undergo thor-
ough ophthalmological evaluation (including
corneal topography) every 6 months, especially
the young patients in whom the disease is
characterized by more rapid progression [4].
On the contrary, in stable keratoconic cases
with contact lens or spectacle intolerance (due
to irregular astigmatism, anisometropia, or high
refractive error), the optimal treatment modal-
ity is the combination of CXL with transep-
ithelial phototherapeutic keratectomy (t-PTK)
and/or topo-guided photorefractive keratec-
tomy in order to regularize the corneal surface
without destabilizing the disease status (Fig. 1)
[70, 74]. Alternatively, corneal irregularity may
be surgically improved by insertion of
intrastromal corneal ring segments (in patients
with irregular astigmatism and corneal thick-
ness not suitable for laser ablation), while in
older patients with stable disease, high refrac-
tive error, and irregular astigmatism, phakic IOL
should be considered [33, 108]. Pseudophakic
toric intraocular lens implantation is a satisfac-
tory option in eyes with stable, mild to
Fig. 1 Keratoconus treatment algorithm. VA visual acuity,
RGP rigid gas-permeable lens, DALK deep anterior
lamellar keratoplasty, PK penetrating keratoplasty, CL
contact lens, Sp spectacle, CXL cornea cross-linking, PRK
photorefractive keratectomy, RLE refractive lens exchange
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moderate keratoconus, and cataract [109], while
in patients older than 50, clear lens surgery with
posterior chamber lens implantation is an
effective alternative (Fig. 1).
In cases where progression of the disease is
established topographically with or without
corneal thinning, CXL treatment is proposed
for the stabilization of the ectatic disease
(Fig. 1). In patients with increased corneal
irregularity and contact lens or spectacle intol-
erance a combination of CXL with additional
refractive procedures could be considered in
order to provide both corneal stability and
functional vision. More specifically, CXL may
be combined with t-PTK and/or PRK wherever
the corneal irregularity may be improved with
laser ablation techniques, provided that after
ablation and before CXL, the corneal thickness
remains over 400 lm [70, 74]. Alternatively, in
patients who do not meet the safety limits
regarding corneal thickness for laser procedure,
ICRS could be used to reshape the cornea and
reduce the refractive error followed by CXL in
order to achieve corneal stability [81]. In cases
with high refractive errors (myopia and regular
astigmatism), performance of CXL may be fol-
lowed by insertion of Phakic IOL with an
interval time of 6–12 months (Fig. 1) [83].
FUTURE OF KERATOCONUS
TREATMENT
All treatment options discussed earlier have
proven efficient and safe in the management of
keratoconus. Latest technological advance-
ments have created a new trend towards less
invasive procedures. The ultimate goal would be
sutureless procedures and less intra- and post-
operative complications that could achieve
permanent corneal flattening and visual
rehabilitation.
Pulse CXL
One hypothesis explaining the shallower effect
observed with accelerated cross-linking proto-
cols is the higher oxygen consumption leading
to oxygen depletion. One way to increase
oxygen concentration in the cornea during
accelerated CXL is to deliver pulsed irradiation
to allow oxygen to diffuse into the stroma dur-
ing non-irradiation intervals. As a result, on–off
pattern protocols may have the potential to
increase the corneal stiffening effect obtained
with the same UV-A dose, and may potentially
lead to a reduction in procedure time by
increasing the treatment efficacy of high irra-
diance CXL. Preliminary results by Peyman
et al. and Mazzotta et al. with pulsed irradiation
are promising, indicating safety equivalent to
the continuous UV exposure protocols, albeit
with greater demarcation line depth [110, 111].
Park et al. recently showed a considerably dee-
per effect in the cornea stroma using accelerated
pulsed UV-A than continuous UV-A [112].
Epi-on Cross-Linking
In an attempt to avoid standard CXL treat-
ment complications and postoperative pain,
several methods have been introduced to
enhance riboflavin penetration through an
intact epithelium. Finding an effective
cross-linking technique with retention of the
epithelium is the subject of many studies.
Riboflavin formulations with added
corneal-enhancing compounds like benzalko-
nium chloride, ethylenediaminetetraacetic
acid, and tetracaine can improve riboflavin
diffusion despite epithelial presence
[113–115]. Intrastromal channels and flaps as
alternative routes have also been proposed
[116, 117]. Significant controversial results
have been reported with the various transep-
ithelial techniques.
Iontophoresis-assisted corneal cross-linking
is a non-invasive approach in which a low-in-
tensity electric current enhances the penetra-
tion of riboflavin into the stroma and facilitates
more precise, homogeneous diffusion of the
ionized molecule through the epithelium [118].
Ex vivo studies on rabbit and human cadaveric
corneas showed that iontophoresis transep-
ithelial cross-linking induced an increase in the
biomechanical resistance of human cornea
comparable to that obtained with the standard
cross-linking procedure.
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Clinical studies have shown an improvement
in BCVA, and no changes in central corneal
thickness and endothelial cell density. How-
ever, recent studies indicate that while
iontophoresis-assisted corneal cross-linking
successfully halts keratoconus progression,
standard CXL seems more effective with deeper
stromal cornea collagen cross-links and better
average topographic results [119, 120]. More-
over, the demarcation line found after ion-
tophoresis is fainter and less deep than that
found after traditional epithelium-off tech-
niques [121].
CXL Using Topography-Guided UV-A
Energy Emission
In addition to varying the depth of cross-linking
by modifying parameters like UV-A irradiance,
total energy dose, andUV-A frequency, the lateral
distribution of cross-link formation in the cornea
may be better controlled through the use of cus-
tomized UV-A illumination patterns that would
allow targeted stiffening of the weakest regions of
thecornea rather thantheconventional approach
of uniformly stiffening the entire central cornea.
A number of ongoing studies are evaluating the
efficacy of the procedures. Mazzotta et al. retro-
spectively examined 21 eyes that underwent
accelerated cross-linking using a UV-A exposure
with anenergy release varying from7.2up to15 J/
cm2, according to the topographic corneal cur-
vature with favorable 1-year results [122]. Nord-
stro¨m et al. reported similar promising results in
their prospective clinical trial [123].
Bowman Layer Transplantation
The first use of Bowman layer transplantation
(BL) was to manage persistent subepithelial
haze after excimer laser surface ablation [124].
Melles and his team came up with the idea to
use BL transplantation to halt keratoconus
progression [125]. The rationale behind Bow-
man transplantation is that since fragmentation
of the Bowman layer is a pathognomic feature
in advanced keratoconus, a partial restoration
of the anatomy might be achieved through a
midstromal implant of an isolated Bowman
layer graft to remodel corneal curvature. At the
same time, stabilization of the ectasia may be
obtained by the Bowman layer splint and
through the wound-healing reaction between
the host stroma and the Bowman layer graft.
Parker et al. performed the technique in 22 eyes
of 19 patients with advanced keratoconus. The
authors reported a decrease on average maxi-
mum keratometry at 1 month after surgery
which remained stable thereafter, and an
improvement in mean BSCVA, with no change
in endothelial cell density. At 5-year follow-up,
Bowman layer transplantation stabilized disease
in 90% of 22 eyes with advanced keratoconus.
The authors concluded that given the low risk
for complications, the procedure is a safe and
effective method of stabilizing keratoconus and
may be performed to postpone penetrating or
deep anterior lamellar keratoplasty [126].
CONCLUSION
Keratoconus management has significantly
changed over the last few years. Cornea clini-
cians nowadays can perform a number of
treatment modalities that can halt disease pro-
gression and alter cornea shape in a safe and
effective way, thus providing optimum visual
results in keratoconus patients. Future devel-
opments may further improve the safety and
efficacy of these therapies. More studies are
needed to provide clinical data to prove their
short- and long-term effectiveness.
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